Akero Therapeutics, Inc.

NASDAQ:AKRO

28.25 (USD) • At close December 27, 2024
Bedrijfsnaam Akero Therapeutics, Inc.
Symbool AKRO
Munteenheid USD
Prijs 28.25
Beurswaarde 1,971,824,575
Dividendpercentage 0%
52-weken bereik 15.32 - 37
Industrie Biotechnology
Sector Healthcare
CEO Dr. Andrew Cheng M.D., Ph.D.
Website https://www.akerotx.com

An error occurred while fetching data.

Over Akero Therapeutics, Inc.

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates,

Vergelijkbare Aandelen

Theseus Pharmaceuticals, Inc. logo

Theseus Pharmaceuticals, Inc.

THRX

4.065 USD

Talaris Therapeutics, Inc. logo

Talaris Therapeutics, Inc.

TALS

2.72 USD

Aadi Bioscience, Inc. logo

Aadi Bioscience, Inc.

AADI

3.21 USD

Eiger BioPharmaceuticals, Inc. logo

Eiger BioPharmaceuticals, Inc.

EIGR

1.725 USD

Radius Health, Inc. logo

Radius Health, Inc.

RDUS

15.23 USD

Icosavax, Inc. logo

Icosavax, Inc.

ICVX

15.31 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)